Esperion Therapeutics, Inc. (ESPR)

Market Cap	144.99M
Revenue (ttm)	102.90M
Net Income (ttm)	-208.39M
Shares Out	113.72M
EPS (ttm)	-2.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	514,670
Open	1.22
Previous Close	1.22
Day's Range	1.21 - 1.28
52-Week Range	0.70 - 8.87
Beta	0.30
Analysts	Buy
Price Target	9.83 (+670.98%)
Earnings Date	Nov 7, 2023

About ESPR

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 26, 2013
• Employees: 199
• Stock Exchange: NASDAQ
• Ticker Symbol: ESPR

Financial Performance

In 2022, ESPR's revenue was $75.48 million, a decrease of -3.79% compared to the previous year's $78.45 million. Losses were -$233.66 million, -13.17% less than in 2021.

Analyst Forecast

According to 7 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is $9.83, which is an increase of 670.98% from the latest price.

Price Target

$9.83

(670.98% upside)

Analyst Consensus: Buy